BACKGROUND: Management of Anderson-Fabry disease (AFD) is contentious, particularly regarding enzyme replacement therapy (ERT). We report results of a Delphi consensus panel on AFD management. METHODS: A survey to gauge consensus among AFD experts was distributed online and responses were analysed. Statements on: 1) diagnosis; 2) when starting ERT; 3) management of ERT infusion and adverse reactions; and 4) follow-up/monitoring response to therapy and progression of disease were included. Responses without consensus were discussed with an enlarged panel and modified to reach consensus. RESULTS: 15 experts responded to the survey. After plenary discussion among the enlarged panel, consensus was reached on most statements. Key points were the use of a target organ biopsy to show Gb3 deposits in symptomatic women with negative molecular analysis, the need for ERT in symptomatic women and in all patients with persistent signs and symptoms±organ damage. It was agreed to assess vital signs before ERT administration and use a 0.2μL filter on infusion to reduce the risk of adverse reactions, that serum should be drawn prior to the first infusion for anti-agalsidase antibody analysis to have a baseline value if a subsequent adverse reaction appears, and that pre-medication is required in those with prior infusion reactions. Holter ECG monitoring, cardiac and brain MRI, renal parameters, and abdominal ultrasound were considered important for the assessment of disease progression and response at ERT. CONCLUSIONS: This consensus supplies guidance to healthcare providers on best practice in the management of patients with AFD and indicates a need for more guidance

Concolino, D., Degennaro, E., Parini, R., Antuzzi, D., Bembi, B., Benso, A., et al. (2014). Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 25(8), 751-756 [10.1016/j.ejim.2014.07.009].

Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease

DIOMEDI, MARINA;
2014-10-01

Abstract

BACKGROUND: Management of Anderson-Fabry disease (AFD) is contentious, particularly regarding enzyme replacement therapy (ERT). We report results of a Delphi consensus panel on AFD management. METHODS: A survey to gauge consensus among AFD experts was distributed online and responses were analysed. Statements on: 1) diagnosis; 2) when starting ERT; 3) management of ERT infusion and adverse reactions; and 4) follow-up/monitoring response to therapy and progression of disease were included. Responses without consensus were discussed with an enlarged panel and modified to reach consensus. RESULTS: 15 experts responded to the survey. After plenary discussion among the enlarged panel, consensus was reached on most statements. Key points were the use of a target organ biopsy to show Gb3 deposits in symptomatic women with negative molecular analysis, the need for ERT in symptomatic women and in all patients with persistent signs and symptoms±organ damage. It was agreed to assess vital signs before ERT administration and use a 0.2μL filter on infusion to reduce the risk of adverse reactions, that serum should be drawn prior to the first infusion for anti-agalsidase antibody analysis to have a baseline value if a subsequent adverse reaction appears, and that pre-medication is required in those with prior infusion reactions. Holter ECG monitoring, cardiac and brain MRI, renal parameters, and abdominal ultrasound were considered important for the assessment of disease progression and response at ERT. CONCLUSIONS: This consensus supplies guidance to healthcare providers on best practice in the management of patients with AFD and indicates a need for more guidance
ott-2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/03 - GENETICA MEDICA
Settore MED/14 - NEFROLOGIA
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Management; Diagnosis; Fabry disease; Treatment
Concolino, D., Degennaro, E., Parini, R., Antuzzi, D., Bembi, B., Benso, A., et al. (2014). Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 25(8), 751-756 [10.1016/j.ejim.2014.07.009].
Concolino, D; Degennaro, E; Parini, R; Antuzzi, D; Bembi, B; Benso, A; Carraro, G; Chimenti, C; Colla, L; Cuonzo, M; Del Rosso, G; Diomedi, M; Feliciani, C; Feriozzi, S; Ficcadenti, A; Frustaci, A; Gnarra, M; Maccarone, M; Mancuso, M; Matucci, A; Mignani, R; Musumeci, B; Nencini, P; Piga, S; Pisani, A; Re, F; Salviati, A; Spada, M; Vultaggio, A; Zachara, ; E., Z; Ml, ; Zoli, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
delphi Fabry.pdf

accesso aperto

Descrizione: articolo
Dimensione 236.06 kB
Formato Adobe PDF
236.06 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/99672
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact